Healthcare [ 6/11 ] | Medical Devices [ 95/148 ]
US | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 10, 23 | 0.13 Increased by +168.42% | 0.12 Increased by +8.33% |
| Jun 28, 23 | 0.11 Increased by +142.31% | 0.16 Decreased by -31.25% |
| Feb 13, 23 | -0.12 Increased by +25.00% | -0.08 Decreased by -50.00% |
| Nov 14, 22 | -0.18 Decreased by -38.46% | -0.21 Increased by +14.29% |
| Aug 9, 22 | -0.19 Decreased by -18.75% | -0.22 Increased by +13.64% |
| Jun 28, 22 | -0.26 Decreased by -73.33% | -0.14 Decreased by -85.71% |
| Feb 14, 22 | -0.16 Increased by +20.00% | -0.13 Decreased by -23.08% |
| Nov 9, 21 | -0.13 Increased by +13.33% | -0.15 Increased by +13.33% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 23 | 574.25 K Increased by +4.28 K% | -2.46 M Increased by +35.11% | Decreased by -427.69% Increased by +98.52% |
| Dec 31, 22 | 0.00 Decreased by -100.00% | -2.77 M Decreased by -9.64% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by -100.00% | -3.95 M Decreased by -96.69% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by -100.00% | -2.91 M Decreased by -38.54% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 13.12 K Decreased by -61.69% | -3.79 M Decreased by -67.26% | Decreased by -28.86 K% Decreased by -336.56% |
| Dec 31, 21 | 17.12 K Decreased by -97.26% | -2.53 M Decreased by -3.48% | Decreased by -14.77 K% Decreased by -3.68 K% |
| Sep 30, 21 | 131.97 K Increased by +N/A% | -2.01 M Decreased by -13.41% | Decreased by -1.52 K% Decreased by N/A% |
| Jun 30, 21 | 131.97 K Increased by +N/A% | -2.10 M Decreased by -48.72% | Decreased by -1.59 K% Decreased by N/A% |
Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.